Transcend Vivoscope key facts
- Manufacturer of high-end biomedical imaging equipment designed to enable in vivo microscopic visualisation of neural and cellular activity.
- It has raised $28.1M; the latest was Later Stage VC ($14.4M) in Feb 2026.
- Notable investors include Shenzhen Capital Group, CAS Star, Beijing State-owned Capital Operation and Management, China Capital Management, Shenzhen Guozhong Venture Capital Management — 20 tracked in total.
- Status: Privately Held (backing).
Who backs Transcend Vivoscope
20+Membership and data by Private Market View
- ·The complete investor list: 20 names
- ·Watch Transcend Vivoscope: the Monday email on marks, rounds and moves
Transcend Vivoscope funding rounds
No funding rounds for Transcend Vivoscope are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Transcend Vivoscope investors
20 investors are on record for Transcend Vivoscope, including Shenzhen Capital Group, CAS Star, Beijing State-owned Capital Operation and Management and China Capital Management.
About Transcend Vivoscope
Manufacturer of high-end biomedical imaging equipment designed to enable in vivo microscopic visualisation of neural and cellular activity. The company offers miniaturised multiphoton microscopes, specialised optical components, and endoscopic imaging systems, enabling neuroscience researchers, clinical clinicians, and pharmaceutical developers to conduct deep-tissue imaging with high spatial and temporal resolution and advance biological research and medical diagnostics.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2016
- Employees
- 100
- Website
- tv-scope.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Transcend Vivoscope doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.